AC Immune amended its 2018 license and collaboration agreement with Eli Lilly to advance Tau aggregation inhibitor small molecules for Alzheimer’s and other neurodegenerative disorders. The amendment reinforces the partnership and could accelerate development timelines and potential milestone/licensing value for AC Immune, representing a modest positive catalyst for the biotech; impact on Lilly is likely neutral-to-mildly positive.
AC Immune amended its 2018 license and collaboration agreement with Eli Lilly to advance Tau aggregation inhibitor small molecules for Alzheimer’s and other neurodegenerative disorders. The amendment reinforces the partnership and could accelerate development timelines and potential milestone/licensing value for AC Immune, representing a modest positive catalyst for the biotech; impact on Lilly is likely neutral-to-mildly positive.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
